T-type calcium channel subunit alpha-1G (CaV3.1)

T-type calcium channel subunit alpha-1G (CaV3.1) is a member of the low-voltage activated (LVA) voltage-gated calcium channel family, encoded by the CACNA1G gene[1][2][7][8]. It forms the ion-conducting pore of T-type calcium channels, which possess unique properties including rapid activation and inactivation kinetics and the ability to open at relatively negative membrane potentials[5][7]. CaV3.1 channels play crucial roles in regulating neuronal excitability, pacemaker activities in both neurons and the heart, thalamocortical oscillations, and rhythmic firing patterns, making them central to a variety of physiological processes, including heart rate generation, sleep rhythms, and hormone secretion[2][4][7][8]. Dysfunction or altered expression of these channels has been linked to diseases such as epilepsy (especially absence seizures), cardiovascular disorders (particularly arrhythmias and hypertension), and certain neuropsychiatric and neurodegenerative conditions[2][6][9]. A range of drugs—including mibefradil, ethosuximide, and certain neurosteroids—target CaV3.1, either selectively or as part of broader T-type channel inhibition, for therapeutic intervention in epilepsy, hypertension, and other disorders[3][4][8]. Safety challenges for these agents include effects on cardiac and CNS function due to the widespread physiological roles of CaV3.1 and limited subtype selectivity of most current inhibitors[2][6][9].

Other names

CACNA1GVoltage-gated calcium channel subunit alpha-1GLow voltage-activated calcium channel alpha 1G subunitCav3.1 T-type calcium channel

Channel blockade (inhibition of T-type calcium influx); Modulation of gating or activation properties; Blockade leads to reduced neuronal/cardiac excitability; Some drugs stabilize inactive state or reduce channel open probability